Diabetic Retinopathy Treatment Market Size, Share and Global Trend By Diabetic Retinopathy Type (Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy), By Treatment Type (Anti-Vascular Endothelial Growth Factor (VEGF) Drug, Laser Surgery, Vitrectomy, Intraocular Steroid Injection), By End User (Hospitals, Ophthalmic Centres, Ambulatory Surgery Centres, Others) and Regional Forecast, 2024-2032

Diabetic retinopathy is a medical disorder, resulting from the complications of diabetes mellitus and is also one of the leading cause of blindness. Diabetic retinopathy is determined by the type of diabetes the individual is diagnosed with, amount of time that the individual has diabetes and the level to which the blood sugar is controlled. The symptoms of diabetic retinopathy include very mild to no symptoms at the beginning of the condition, blurred and fluctuating vision, impairment of color vision, eventually leading to blindness.

Management of diabetes is critical towards the prevention and successful treatment of diabetic retinopathy because excessive sugar in the blood can lead to the blocking of the tiny blood vessels nourishing the retina, cutting off the blood supply. This results in the formation of new blood vessels which are not perfectly developed, leading to being susceptible to leaks easily.

Some of the associated complications of diabetic retinopathy include blindness, cataracts, vitreous hemorrhage, glaucoma, and retinal detachment. Diabetic retinopathy is highly treatable, even individuals diagnosed with advanced diabetic retinopathy have an estimated 95% chance of retaining their vision before the retina is permanently damaged.

The global diabetic retinopathy treatment market is anticipated to grow at faster CAGR, owing to a number of factors such as the increasing prevalence of diabetic retinopathy, increasing prevalence of diabetes of all types, and increasing incidence of associated complications such as blindness.

Moreover, increasing research advances in treatment and prevention and rising demand for preventive medical care through regular eye examinations is expected to boost the growth of the global diabetic retinopathy market during the forecast period. According to research conducted by the Centres for Disease Control and Preventions (CDC), in 2017, an estimated 4.2 million adults were suffering from diabetic retinopathy in the U.S.

Some of the factors limiting the growth of the global diabetic retinopathy treatment market are the negligence of people to the symptoms of diabetic retinopathy, poor management of treatment of diabetic retinopathy and increased risk of the associated side effects of the treatment options.

Key Players Covered

Some of the major companies that are present in the global diabetic retinopathy treatment market are F. Hoffmann-La Roche Ltd, Alimera Sciences, Abbott, Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Bayer AG, and Oxurion NV, and others.

SEGMENTATION

Among the segmentation, anti-vascular endothelial growth factor (VEGF) drug in the treatment type segment is expected to hold a considerable share in the market during the forecast period. Proven significance in the treatment of diabetic retinopathy in clinical trials is expected to boost the adoption of anti-vascular endothelial growth factor (vegf) drug by 2026.

Key Insights 

• The regulatory scenario for key countries


• Pipeline Analysis


• Epidemics of Diabetic Retinopathy – Key Countries


• New Product Launches by Key Players


• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis

North America is expected to account for the largest share in the global diabetic retinopathy market due to the increasing prevalence of diabetic retinopathy and associated complications, rise in the incidence of diabetes, and increasing demand for preventive care. Additionally, increasing awareness regarding regular eye examinations amongst populations, established healthcare systems, and access to advanced technologies is anticipated to boost the growth of the diabetic retinopathy treatment market in North America by 2026. The Asia Pacific expected to be is the fastest emerging market due to the rapidly increasing prevalence of diabetic retinopathy coupled with increasing disposable incomes and developing healthcare systems in emerging economies.

Key Industry Developments

• In July 2018, Government of Australia announced funding provision for Nation Diabetes Eye Screening Program. The program is Australia’s first ever program to diagnose and treat people suffering from diabetic retinopathy across the Australia.
• In April 2018, FDA approved first ever artificial intelligence based diagnostic system designed and developed by IDx Technologies Inc. The newly developed system enables to detect diabetic retinopathy amongst patients during regular clinic visits.
• In April 2017, FDA approved Lucentis (ranibizumab injection) 0.3 mg, developed by Genentech, Inc., subsidiary of Roche group, for the treatment of diabetic retinopathy on monthly basis. It is the only FDA approved drug available for all types of diabetic retinopathy treatments.